Relief Therapeutics announces new study results for RLF-OD032, files provisional patents.

Relief Therapeutics announced new study results for its drug RLF-OD032 and has filed provisional patents related to its findings. The company aims to advance its research and protect its innovations in the therapeutic space. Further details on the study's outcomes and implications were not specified in the report.

October 25, 2024
3 Articles

Further Reading